Core Insights - Exicure, Inc. (NASDAQ:XCUR) stock experienced a significant increase of 63.23%, reaching $8.70, following the announcement of positive results from its Phase 2 trial of burixafor in multiple myeloma patients [6] Group 1: Trial Results - Approximately 90% of study participants achieved the primary endpoint of collecting ≥2 × 10⁶ CD34+ cells/kg within two leukapheresis sessions [2][3] - Among the 19 participants, 17 (89.5%) met the primary endpoint, with two requiring an additional session to achieve the target [3] - The median time to neutrophil engraftment was 13 days, and the median time to platelet engraftment was 17.5 days for those who proceeded to transplant [4] Group 2: Mechanism and Efficacy - Burixafor is an investigational small molecule that blocks CXCL12 binding to CXCR4 receptors, facilitating rapid mobilization of hematopoietic progenitor cells from the bone marrow [2] - The combination of burixafor with propranolol enhanced mobilization by inhibiting the β2-adrenergic receptor [3] - Peak peripheral levels of CD34+ cells were observed within one hour of burixafor administration, allowing for same-day administration and apheresis [4] Group 3: Safety Profile - The burixafor combination was well tolerated, with no related adverse events exceeding Grade 2 [6] - Among participants with prior exposure to daratumumab, 87.5% achieved the primary endpoint, indicating the treatment's effectiveness even in previously treated patients [5]